The Effects of Omega-3 Fatty Acids on Peripheral Arterial Disease II

Completed · Phase 2 · Has a placebo group

Conditions studied: Peripheral Arterial Disease

In brief

Investigators hypothesize that high-dose n-3 polyunsaturated fatty acids (PUFA) oral supplementation will improve systemic inflammation, vascular function, and symptomatic status of patients with PAD. Investigators will explore novel mechanistic pathways by which n-3 PUFA affect PAD, evaluating the role of specialized lipid mediators involved in the resolution of inflammation.

Key facts

Study ID

NCT01979874

Run by

University of California, San Francisco

People needed

26

Starts

2014-02-01

Expected to finish

2017-09-01

Last updated by the study team

2019-07-22

Who can join

Age: 50 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Intermittent claudication (Rutherford 1-3)
• One of the following:
• Resting or exercise ankle-brachial index (ABI) <0.9
• toe pressure < 70 mm Hg
• documentation on imaging of greater than or equal to 50% stenosis in segments of aortoiliac arteries, femoral arteries, or tibial arteries
• Age 50 and more

You may not qualify if…

• Critical limb ischemia
• Hypersensitivity/allergies to fish or seafood
• Already on n-3 PUFA or equivalent
• Significant renal, hepatic, and inflammatory disease
• Concurrent severe infections
• Acute illness (myocardial infarction, stroke, major surgery within 30 days)
• Receiving immunosuppressive medications or steroids
• Age < 50

Where it is running

• San Francisco Veterans Affairs Medical Center — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.